相关实验视频

Updated: Jun 29, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

美国患者的现实患者特征和治疗模式美国患者患有晚期非小细胞肺癌

Hozefa A Divan¹, Marisa A Bittoni², Ashok Krishna³

¹Sanofi, Inc., 450 Water Street, Cambridge, MA, 02142, USA.

|April 5, 2024

概括

现实数据显示,一线高级非小细胞肺癌 (NSCLC) 治疗从单独的免疫疗法转向化疗免疫疗法. 这种演变发生在2016年至2020年之间,在NSCLC患者中增加了生物标志物测试.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
现实世界的证据.

背景情况:

针对非小细胞肺癌 (NSCLC) 的临床试验可能不代表现实世界多样化的患者群体.
了解真实世界的患者特征和治疗模式对于有效的NSCLC管理至关重要.

研究的目的:

描述美国NSCLC患者的现实患者特征和一线治疗模式.
在一段时间内分析高级NSCLC的治疗演变.

主要方法:

使用来自ConcertAI Patient360 NSCLC数据库的电子医疗记录进行的观察性,回顾性队列研究.
分析包括美国成年人局部晚期或转移性NSCLC在2016年7月至2020年12月期间启动一线抗编程细胞死亡蛋白1/编程细胞死亡连接体1 (PD-1/PD-L1) 治疗.

主要成果:

分析了2175名NSCLC患者的队列,平均年龄为68岁;26.2%是≥75岁.
大多数患者患有4期NSCLC (96.4%),非状腺癌 (66.4%) 和多个转移部位 (31.2%有≥2个转移部位),包括大脑转移 (22.9%).
第一线治疗从2016年的90.2%的单剂抗PD-1/PD-L1转移到2020年的60.2%的组合化疗免疫治疗.

结论:

美国先进NSCLC的第一线治疗模式在2016年至2020年之间从单一疗法演变为组合化疗免疫疗法.
在此期间,生物标志物测试增加了.
对异质NSCLC患者群体的治疗策略进行进一步研究是有必要的.

关键词:

非小细胞肺癌是非小细胞肺癌.观察性研究是一种观察性研究.这是一种PD-1抑制剂.这是一种PD-L1抑制剂.患者的特征患者的特征现实世界的证据.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...